Engimata is an early stage biopharma company located in the San Francisco Bay Area. Engimata has developed a COVID-19 vaccine, using its platform nano lipid particle technology with recombinant viral surface proteins to mimic those found on the SARS-CoV-2 coronavirus particle.
